# A Prospective Multi-centered Randomized Controlled Trial on Fruquintinib in Combination With HAIC in the Treatment of Liver Metastatic Colorectal Cancer After Failure of Second-line Systematic Therapy

> **NCT05511051** · PHASE2 · UNKNOWN · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 102 (estimated)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** Fruquintinib
- **DRUG:** HAIC

## Key facts

- **NCT ID:** NCT05511051
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-02-01
- **Primary completion:** 2024-08-01
- **Final completion:** 2024-12-31
- **Target enrollment:** 102 (ESTIMATED)
- **Last updated:** 2022-08-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05511051

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05511051, "A Prospective Multi-centered Randomized Controlled Trial on Fruquintinib in Combination With HAIC in the Treatment of Liver Metastatic Colorectal Cancer After Failure of Second-line Systematic Therapy". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05511051. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*